PREDICTORS FOR THE INITIATION OF A BASAL SUPPORTED ORAL THERAPY (BOT) IN TYPE 2 DIABETIC PATIENTS UNDER REAL-LIFE CONDITIONS IN GERMANY

被引：0
|
作者：
Hammer, H. [4 ]
Dippel, F. W. [1 ]
Kostev, K. [2 ]
Fuchs, S. [3 ]
Kotowa, W. [3 ]
机构：
[1] Sanofi Aventis Deutschland GmbH, Berlin, Germany
[2] IMS Hlth GmbH & Co OHG, Frankfurt, Germany
[3] IMS Hlth GmbH & Co OHG, Nurnberg, Germany
[4] Dr Med Harm Hammer, Bremen, Germany
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72065-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A284 / A284
页数：1
相关论文
共 50 条
  • [1] Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany
    Kostev, Karel
    Dippel, Franz-Werner
    PRIMARY CARE DIABETES, 2012, 6 (04) : 329 - 335
  • [2] Different persistence on initial basal supported oral therapy in Type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany
    Pfohl, M.
    Dippel, F-W
    Kostev, K.
    Fuchs, S.
    Kotowa, W.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (11) : 761 - 766
  • [3] Amputation rate and risk factors in type 2 patients with diabetic foot syndrome under real-life conditions in Germany
    Pscherer, Stephan
    Dippel, Franz-Werner
    Lauterbach, Silke
    Kostev, Karel
    PRIMARY CARE DIABETES, 2012, 6 (03) : 241 - 246
  • [4] EARLY Study: Early Basal Insulin Therapy under Real-Life Conditions in Type 2 Diabetics
    Hanefeld, M.
    Fleischmann, H.
    Landgraf, W.
    Pistrosch, F.
    DIABETES STOFFWECHSEL UND HERZ, 2012, 21 (02): : 91 - 97
  • [5] Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions
    Gentile, Sandro
    Strollo, Felice
    Viazzi, Francesca
    Russo, Giuseppina
    Piscitelli, Pamela
    Ceriello, Antonio
    Giorda, Carlo
    Guida, Piero
    Fioretto, Paola
    Pontremoli, Roberto
    De Cosmo, Salvatore
    JOURNAL OF DIABETES RESEARCH, 2018, 2018
  • [6] COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL THERAPY (BOT) IN GERMANY
    Neilson, A.
    Pscherer, S.
    Dippel, F. W.
    Dietrich, E. S.
    VALUE IN HEALTH, 2009, 12 (07) : A408 - A408
  • [7] Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin
    Quinzler, Renate
    Ude, Miriam
    Franzmann, Alexandra
    Feldt, Sandra
    Schuessell, Katrin
    Leuner, Kristina
    Mueller, Walter E.
    Dippel, Franz-Werner
    Schulz, Martin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (01) : 24 - 32
  • [8] TREATMENT OUTCOMES FOLLOWING INITIATION OF DAPAGLIFLOZIN OR BASAL SUPPORTED ORAL THERAPY AMONG TYPE 2 DIABETES PATIENTS IN PRIMARY CARE PRACTICES IN GERMANY
    Ehlken, B.
    Kostev, K.
    VALUE IN HEALTH, 2016, 19 (07) : A666 - A667
  • [9] DIFFERENT INJECTION FREQUENCIES OF BASAL INSULINS IN TYPE 2 DIABETES PATIENTS UNDER REAL-LIFE CONDITIONS: A RETROSPECTIVE DATABASE ANALYSIS
    Kostev, K.
    Dippel, F. W.
    Rathmann, W.
    VALUE IN HEALTH, 2013, 16 (07) : A450 - A450
  • [10] Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy
    Takahara, Mitsuyoshi
    Shiraiwa, Toshihiko
    Ohtoshi, Kentaro
    Kaneto, Hideaki
    Katakami, Naoto
    Matsuoka, Taka-aki
    Shimomura, Iichiro
    JOURNAL OF DIABETES INVESTIGATION, 2012, 3 (06) : 510 - 516
12345